• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [17111 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Norwegian Institute of Public Health (NIPH) 177Lutetium-based peptide receptor radionuclide therapy for treating neuroendocrine tumours: a health technology assessment
2018     National Institute for Health and Care Excellence (NICE) Laparoscopic ventral mesh rectopexy for internal rectal prolapse. NICE interventional procedures guidance 618
2018     Norwegian Institute of Public Health (NIPH) Diagnostic accuracy, clinical effectiveness and budget impact of screening BRCA1/2 mutation carriers by MRI. A health technology assessment
2018     National Institute for Health and Care Excellence (NICE) Intranasal phototherapy for allergic rhinitis. NICE interventional procedures guidance 616
2018     NIHR Health Technology Assessment programme Nurse staffing levels, missed vital signs and mortality in hospitals: retrospective longitudinal observational study.
2018     Norwegian Institute of Public Health (NIPH) Bariatric surgery for Type 2 Diabetes and a body mass index below 35
2018     National Institute for Health and Care Excellence (NICE) Golimumab for treating non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 497
2018     National Institute for Health and Care Excellence (NICE) Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer. NICE interventional procedures guidance 614
2018     National Institute for Health and Care Excellence (NICE) Lenvatinib with everolimus for previously treated advanced renal cell carcinoma. NICE technology appraisal guidance 498
2018     National Institute for Health and Care Excellence (NICE) Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. NICE interventional procedures guidance 615
2018     National Institute for Health and Care Excellence (NICE) Glecaprevir–pibrentasvir for treating chronic hepatitis C. NICE technology appraisal guidance 499
2018     National Institute for Health and Care Excellence (NICE) Percutaneous balloon valvuloplasty for fetal critical aortic stenosis. NICE interventional procedures guidance 613
2018     National Institute for Health and Care Excellence (NICE) Ceritinib for untreated ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 500
2018     National Institute for Health and Care Excellence (NICE) Robot-assisted kidney transplant. NICE interventional procedures guidance 609
2018     Swiss Federal Office of Public Health (FOPH) Knee arthroscopy for the treatment of degenerative changes
2018     National Institute for Health and Care Excellence (NICE) Intrabeam radiotherapy system for adjuvant treatment of early breast cancer. NICE technology appraisal guidance 501
2018     National Institute for Health and Care Excellence (NICE) Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 611
2018     National Institute for Health and Care Excellence (NICE) Ibrutinib for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 502
2018     National Institute for Health and Care Excellence (NICE) Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma. NICE interventional procedures guidance 612
2018     NIHR Health Technology Assessment programme Systematic review of treatment of dry age-related macular degeneration and Stargardt's disease
2018     National Institute for Health and Care Excellence (NICE) Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer. NICE technology appraisal guidance 503
2018     National Institute for Health and Care Excellence (NICE) Nerve transfer to partially restore upper limb function in tetraplegia. NICE interventional procedures guidance 610
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma
2018     National Institute for Health and Care Excellence (NICE) Pirfenidone for treating idiopathic pulmonary fibrosis. NICE technology appraisal guidance 504
2018     National Institute for Health and Care Excellence (NICE) Mosaicplasty for symptomatic articular cartilage defects of the knee. NICE interventional procedures guidance 607
2018     NIHR Health Technology Assessment programme Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2018     National Institute for Health and Care Excellence (NICE) Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C. NICE technology appraisal guidance 507
2018     National Institute for Health and Care Excellence (NICE) Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina. NICE interventional procedures guidance 608
2018     National Institute for Health and Care Excellence (NICE) Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee. NICE technology appraisal guidance 508
2018     National Institute for Health and Care Excellence (NICE) Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease. NICE interventional procedures guidance 606
2018     National Institute for Health and Care Excellence (NICE) Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer. NICE technology appraisal guidance 509
2018     National Institute for Health and Care Excellence (NICE) Aortic valve reconstruction with processed bovine pericardium. NICE interventional procedures guidance 604
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018
2018     National Institute for Health and Care Excellence (NICE) Brodalumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 511
2018     National Institute for Health and Care Excellence (NICE) Tivozanib for treating advanced renal cell carcinoma. NICE technology appraisal guidance 512
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Subcutaneous implantable cardioverter defibrillator (ICD)
2018     National Institute for Health and Care Excellence (NICE) Obinutuzumab for untreated advanced follicular lymphoma. NICE technology appraisal guidance 513
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Lymphovenous anastomoses in patients with primary and secondary lymphoedema
2018     National Institute for Health and Care Excellence (NICE) Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen. NICE technology appraisal guidance 515
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Allogeneic mesenchymal stem cells for Crohn’s disease-associated complex perianal fistulas
2018     National Institute for Health and Care Excellence (NICE) Cabozantinib for treating medullary thyroid cancer. NICE technology appraisal guidance 516
2018     NIHR Health Technology Assessment programme Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT
2018     NIHR Health Technology Assessment programme Options for possible changes to the blood donation service: health economics modelling
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Meniscal allograft transplantation for post-meniscectomy syndrome
2018     National Institute for Health and Care Excellence (NICE) Avelumab for treating metastatic Merkel cell carcinoma. NICE technology appraisal guidance 517
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Baroreceptor activation therapy for treatment-resistant hypertension
2018     National Institute for Health and Care Excellence (NICE) Tocilizumab for treating giant cell arteritis. NICE technology appraisal guidance 518
2018     National Institute for Health and Care Excellence (NICE) Burosumab for treating X-linked hypophosphataemia in children and young people. NICE highly specialised technologies guidance 8
2018     NIHR Health Technology Assessment programme The Patient Centred Assessment Method for improving nurse-led biopsychosocial assessment of patients with long-term conditions: a feasibility RCT
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Carbon ion beam radiotherapy (CIRT) for cancer treatment: a systematic review of effectiveness and safety for 12 oncologic indications
2018     National Institute for Health and Care Excellence (NICE) Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 520
2018     NIHR Health Technology Assessment programme Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC
2018     National Institute for Health and Care Excellence (NICE) Guselkumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 521
2018     NIHR Health Technology Assessment programme Self-care support for children and adolescents with long-term conditions: the REfOCUS evidence synthesis
2018     NIHR Health Technology Assessment programme Therapy interventions for children with neurodisabilities: a qualitative scoping study
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)
2018     National Institute for Health and Care Excellence (NICE) Midostaurin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 523
2018     NIHR Health Technology Assessment programme Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine
2018     National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma. NICE technology appraisal guidance 524
2018     NIHR Health Technology Assessment programme The West Midlands ActiVe lifestyle and healthy Eating in School children (WAVES) study: a cluster randomised controlled trial testing the clinical effectiveness and cost-effectiveness of a multifaceted obesity prevention intervention programme targeted at children aged 6-7 years
2018     NIHR Health Services and Delivery Research programme Understanding employee whistleblowing in health care
2018     NIHR Health Technology Assessment programme The West Midlands ActiVe lifestyle and healthy Eating in School children (WAVES) study: a cluster randomised controlled trial testing the clinical effectiveness and cost-effectiveness of a multifaceted obesity prevention intervention programme targeted at children aged 6-7 years
2018     Penn Medicine Center for Evidence-based Practice (CEP) Testing for clostridium difficile in oncology patients
2018     National Institute for Health and Care Excellence (NICE) Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. NICE technology appraisal guidance 525
2018     NIHR Health Services and Delivery Research programme A meta-ethnography of healthcare professionals' experience of treating adults with chronic non-malignant pain to improve the experience and quality of healthcare
2018     NIHR Health Technology Assessment programme Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT)
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Supporting children who have parents with mental disorders in Tyrol: A mapping of existing Tyrolean support and societal structures
2018     Penn Medicine Center for Evidence-based Practice (CEP) Securement of Arterial Catheters
2018     National Institute for Health and Care Excellence (NICE) Arsenic trioxide for treating acute promyelocytic leukaemia. NICE technology appraisal guidance 526
2018     NIHR Health Services and Delivery Research programme Predictive risk stratification model: a randomised stepped-wedge trial in primary care (PRISMATIC)
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Prevalence of mental disorders and uptake of mental health services in Tyrol: An analysis of epidemiological literature and administrative data from the Tyrolean health insurance
2018     Penn Medicine Center for Evidence-based Practice (CEP) Guidance for Prostate Cancer Screening
2018     National Institute for Health and Care Excellence (NICE) Beta interferons and glatiramer acetate for treating multiple sclerosis. NICE technology appraisal guidance 527
2018     NIHR Health Technology Assessment programme Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT
2018     NIHR Health Technology Assessment programme Advantages and limitations of virtual online consultations in a NHS acute trust: the VOCAL mixed-methods study
2018     NIHR Health Services and Delivery Research programme Clinical leadership in service redesign using Clinical Commissioning Groups: a mixed-methods study
2018     Penn Medicine Center for Evidence-based Practice (CEP) Risk Factors for Surgical Site Infection and Infection Prevention in Elective Spine Surgery
2018     National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 529
2018     NIHR Health Technology Assessment programme Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT
2018     NIHR Public Health Research (PHR) programme Cluster randomised controlled trial and economic and process evaluation to determine the effectiveness and cost effectiveness of a novel intervention [Healthy Lifestyles Programme (HeLP)] to prevent obesity in school children
2018     Penn Medicine Center for Evidence-based Practice (CEP) Venous Thromboembolism Prevention for Obese Patients
2018     National Institute for Health and Care Excellence (NICE) Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy. NICE technology appraisal guidance 530
2018     NIHR Public Health Research (PHR) programme Collaborative case management to aid return to work after long-term sickness absence: a pilot randomised controlled trial
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)
2018     Penn Medicine Center for Evidence-based Practice (CEP) Scales for Assessing Patients Receiving Moderate Sedation
2018     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. NICE technology appraisal guidance 531
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinaemia
2018     Penn Medicine Center for Evidence-based Practice (CEP) The Effect of Electronic Medical Record Alerts on Provider Wellness
2018     Agency for Healthcare Research and Quality (AHRQ) Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents
2018     National Institute for Health and Care Excellence (NICE) Ocrelizumab for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 533
2018     NIHR Health Technology Assessment programme Lamotrigine for people with borderline personality disorder: a RCT
2018     National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 534
2018     National Institute for Health and Care Excellence (NICE) Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine. NICE technology appraisal guidance 535
2018     NIHR Health Technology Assessment programme Improving the Quality of Dentistry (IQuaD): A cluster factorial randomised controlled trial comparing the effectiveness and cost-benefit of oral hygiene advice and/or periodontal instrumentation with routine care for the prevention and management of periodontal disease in dentate adults attending dental primary care
2018     Agency for Healthcare Research and Quality (AHRQ) Breastfeeding programs and policies, breastfeeding uptake, and maternal health outcomes in developed countries
2018     National Institute for Health and Care Excellence (NICE) Alectinib for untreated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 536
2018     National Institute for Health and Care Excellence (NICE) Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 537
2018     National Institute for Health and Care Excellence (NICE) Dinutuximab beta for treating neuroblastoma. NICE technology appraisal guidance 538